sees qtr-four non-gaap earnings per share $num-one to $num-two.
issues qtr-four revenue and earnings per share guidance.
qtrly revenue of $7.8 billion was flat year-over-year as reported and grew num-one% organic.
expects qtr-four organic revenue growth of approximately num-one%.
qtr-three revenue results reflect unfavorable market impact of covid and health system labor shortages on medical device procedure volumes.
impact of covid resurgence on healthcare procedure volumes, particularly in u.s., peaked in final weeks of our quarter in january.
expect healthcare procedures to reaccelerate post-omicron.